LDL @entity165 as a novel risk factor for contrast-induced @entity810 in XXXX undergoing percutaneous coronary intervention.

@entity1 @entity32 @entity712 @entity409 @entity11429 @entity810 @entity1011 @entity583 @entity165
BACKGROUND: Low density lipoprotein @entity165 ( @entity11429 ) is associated with @entity409 , @entity32 and increased vasoconstriction, which are involved in the development of contrast-induced @entity810 (CI-AKI). However, whether @entity11429 is an independent risk factor of CI-AKI in @entity1 undergoing percutaneous coronary intervention (PCI) is unknown. METHODS: We prospectively enrolled 3236 consecutive @entity1 undergoing PCI between January 2010 and September 2012. Multivariate logistic regression analysis was used to determine whether @entity11429 is an independent risk factor of CI-AKI. CI-AKI was defined as an absolute increase in serum @entity1011 of >= 0.5  mg/dL or >= 25% over the baseline value within 48-72  h after contrast exposure. RESULTS: CI-AKI was observed in 338 @entity1 (10.4%). @entity1 with CI-AKI had a significantly higher rate of in hospital mortality (4.4% vs. 0.5%, p  <  0.001), and significantly higher rates of other in hospital complications compared with those without CI-AKI. The @entity11429 quartiles were as follows: Q1 (<2.04  mmol/L), Q2 (2.04-2.61  mmol/L), Q3 (2.61-3.21  mmol/L) and Q4 (>3.21  mmol/L). @entity1 with high baseline @entity11429 levels were more likely to develop CI-AKI and composite end points including all-cause mortality, renal replacement therapy, non-fatal @entity583 , @entity712 , target vessel revascularization or cerebrovascular accident during the observation period of hospitalization (8.9%, 9.9%, 10.5%, 12.6%, p  =  0.001, and 5.0%, 5.2%, 6.1%, 8.1%, respectively; p  =  0.007). Univariate logistic analysis showed that @entity11429 levels (increment 1  mmol/L) were significantly associated with CI-AKI (odds ratio  =  1.25, 95% confidence interval (CI), 1.11-1.39, p  <  0.001). Furthermore, @entity11429 remained a significant risk factor of CI-AKI (odds ratio  =  1.23, 95% CI, 1.04-1.45, p  =  0.014), even after adjusting for potential confounding risk factors. CONCLUSIONS: Measurement of plasma @entity11429 concentrations in @entity1 undergoing PCI may be helpful to identify those who are at risk of CI-AKI and poor in hospital outcomes.
